Advances in next-generation sequencing are enabling larger panel sizes and increased sensitivities for liquid biopsies. These advances lead to a need for patient-like reference materials with more clinically relevant alterations at lower levels than before.
To address this need, LGC SeraCare generated novel circulating tumor DNA (ctDNA) reference materials that combine much of the content of Seraseq ctDNA reference materials and add additional variants and copy number alterations. Because limits of detection of individual mutations are now at or below 0.2 percent variant allele frequency in some ctDNA assays, SeraCare also reduced the lowest VAF from 0.1 percent to 0.01 percent.
This poster from LGC SeraCare provides data on the initial testing of new circulating tumor DNA reference materials that incorporate updated clinically relevant alterations and copy number variants with the lowest variant allele frequency reduced from 0.1 percent to 0.01 percent to accommodate larger NGS panels with increased sensitivities.
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences